Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label atomoxetine study in children and adolescents with ADHD with or without comorbid conditions
2005-005701-32Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Primary endpoint: Mean change in CHIP-CE Achievement domain score. Started Mar 2006; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2005-005701-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005701-32.